Commentary: FDA nonapprovals stall life-saving therapies

Mark Thornton, a former medical officer in the FDA Office of Oncology Products, criticized the agency for failing to approve two "safe, promising" therapies designed to stimulate a patient's immune system to fight cancer. "While our lawmakers obsess over FDA 'safety reforms,' no one is holding this government agency accountable for its complicity in stalling therapies for life-threatening diseases," Thornton said.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
CT
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston-Salem, NC